4,093 Shares of DaVita Inc. $DVA Purchased by Axecap Investments LLC

Axecap Investments LLC acquired a new position in shares of DaVita Inc. (NYSE:DVA) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 4,093 shares of the company’s stock, valued at approximately $716,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. CWA Asset Management Group LLC lifted its position in shares of DaVita by 15.9% during the third quarter. CWA Asset Management Group LLC now owns 26,064 shares of the company’s stock worth $4,559,000 after purchasing an additional 3,574 shares in the last quarter. IFP Advisors Inc grew its stake in shares of DaVita by 44.4% during the third quarter. IFP Advisors Inc now owns 631 shares of the company’s stock valued at $110,000 after purchasing an additional 194 shares during the last quarter. Counterpoint Mutual Funds LLC increased its holdings in shares of DaVita by 56.3% in the third quarter. Counterpoint Mutual Funds LLC now owns 51,875 shares of the company’s stock valued at $9,074,000 after purchasing an additional 18,685 shares in the last quarter. Pension & Wealth Management Advisors Inc. acquired a new stake in shares of DaVita in the third quarter valued at approximately $164,000. Finally, V Square Quantitative Management LLC increased its holdings in shares of DaVita by 34.5% in the third quarter. V Square Quantitative Management LLC now owns 1,859 shares of the company’s stock valued at $325,000 after purchasing an additional 477 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Price Performance

DVA opened at $175.13 on Wednesday. The company has a market cap of $11.17 billion, a price-to-earnings ratio of 14.33, a price-to-earnings-growth ratio of 0.48 and a beta of 0.80. The firm has a 50 day simple moving average of $180.48 and a 200 day simple moving average of $191.24. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $247.49.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The firm had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.50 billion. During the same period last year, the firm earned $2.95 earnings per share. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, analysts expect that DaVita Inc. will post 14.57 EPS for the current year.

Wall Street Analyst Weigh In

DVA has been the topic of several research reports. Weiss Ratings raised DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, October 9th. TD Cowen upgraded DaVita from a “hold” rating to a “buy” rating and increased their price objective for the company from $201.00 to $220.00 in a research report on Friday, August 7th. Barclays increased their price objective on DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 5th. Truist Financial lowered their target price on DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a research note on Friday, August 7th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $265.00 target price on shares of DaVita in a research report on Wednesday, August 5th. Four equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, DaVita presently has an average rating of “Moderate Buy” and a consensus target price of $233.43.

About DaVita

DaVita Inc (NYSE: DVA) is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.